Purple Biotech Ltd. - American Depositary Shares (PPBT)
Competitors to Purple Biotech Ltd. - American Depositary Shares (PPBT)
Adaptimmune Therapeutics PLC ADAP +0.00
Adaptimmune Therapeutics focuses on developing T-cell therapies for cancer, similar to Purple Biotech's approach in targeting tumor microenvironments to enhance immune responses. Both companies are engaged in innovative cancer immunotherapy, which places them in direct competition for investor interest and market share in the oncology space. However, Adaptimmune has an established pipeline with several clinical trials in advanced stages, which may provide them with a competitive edge.
Iovance Biotherapeutics, Inc. IOVA +0.93%
Iovance specializes in cell therapy solutions aimed at melanoma and other solid tumors, competing directly with Purple Biotech in the cancer treatment market. They utilize a different therapeutic approach primarily focused on tumor-infiltrating lymphocyte (TIL) therapy. Iovance benefits from a more advanced clinical portfolio and strategic partnerships, which may currently place them at a competitive advantage over Purple Biotech.
Marinomed Biotech AG
Marinomed Biotech focuses on immunological and antiviral therapies, providing alternatives to Purple Biotech in the broader field of immune-related diseases, including cancer. While their primary focus is not exclusively on oncology, their innovative approaches in therapy development help them secure partnerships and funding that can result in a market advantage. However, Purple Biotech's specialization in the tumor microenvironment may limit direct competition, although having diverse applications can bolster their market presence.
Oncology Phase 1 Development
Oncology Phase 1 Development companies also work on early-stage cancer therapies that might intersect with Purple Biotech's interests. They commonly share similar target demographics of investors and need to demonstrate efficacy and safety of their treatments. However, if a competitor has a particularly robust early-stage clinical trial data, they may attract more partnerships with big pharmaceutical companies, giving them a potentially leading position in the oncology sector.